Hydromorphone Hydrochloride Tablet, Extended Release
Product Images NDC 72865-170

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Hydromorphone Hydrochloride (NDC 72865-170). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

12 mg (12 mg 100s)

12 mg (12 mg 100s)
Each tablet contains Hydromorphone and it is recommended to swallow the tablet whole without breaking, crushing or chewing it. There is dosing information available in the package insert. These extended-release tablets must be stored between 20 to 25 degrees Celsius. The product is manufactured by XLCare Pharmaceuticals, Inc. and is only for opioid-tolerant patients. The medication guide is provided separately to each patient and must be dispensed by the pharmacist. Manufacturing is done by Ascent Pharmaceuticals, Inc.*
FDA Label Image

16 mg (16 mg 100s)

16 mg (16 mg 100s)
HYDROmorphone Hydrochloride Extended-Release Tablets is a prescription medication that is indicated for the management of pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. This medication is available in tablet form with each tablet containing 16 mg of Hydromorphone Hydrochloride. It is important to note that the medication guide should be dispensed separately to each patient and should be taken orally once daily. The tablets should not be crushed, broken or chewed, and should be swallowed whole. Dosage information can be found in the package insert. It is manufactured by XLCare Pharmaceuticals, and should be stored at a temperature of 20° to 25°C (68° to 77°F).*
FDA Label Image

32 mg (32 mg 100s)

32 mg (32 mg 100s)
This is a pharmaceutical product called HYDROmorphone Hydrochloride Extended-Release Tablets used for pain management, and is only to be used by opioid-tolerant patients. Each tablet contains 1! 2mg of Hydromorphone Hydrochloride. Patients are advised to swallow the tablet whole and not crush or chew it. The medication guide provided separately to each patient should be dispensed by the pharmacist. For dosing information, see the package insert. XLCare Pharmaceuticals, Inc. located in Lawrenceville, Georgia, manufactured for this product by Ascent Pharmaceuticals, Inc located in Central Islip, New York. The batch was revised in October 2020.*
FDA Label Image

8 mg (8 mg 100s)

8 mg (8 mg 100s)
This is a description of Hydrochloride tablets manufactured by XLCare Pharmaceuticals, intended for opioid-tolerant patients. The tablets should be swallowed whole without crushing or chewing, and there is information in the package insert for dosing. They should be stored at controlled room temperature. Each bottle contains 100 tablets, and they are manufactured by Ascent Pharmaceuticals Inc. Pharmacists should dispense the medication guide separately to each patient.*
FDA Label Image

Fig-1 (Figure 1)

Fig-1 (Figure 1)
FDA Label Image

Fig-2 (Figure 2)

Fig-2 (Figure 2)
This appears to be a description of the improvement of patients using a medication called "Hydomaphone Hydchoride" in extended release tablets that work for twelve weeks. There is a percentage listed under "Patients improved" and "Percent of reduction/improvement in pain", but it is unclear what exactly is being measured or compared.*
FDA Label Image

Structure (Structure)

Structure (Structure)
FDA Label Image

Table-5 (Table 5)

Table-5 (Table 5)
This appears to be a table containing dosages, time intervals, and measured values of a medical treatment or drug. The text includes measurements such as AUC and CMAX for different doses and regimens over various time periods. It is likely that the text is describing results from a clinical trial or study.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.